c-MET as a potential therapeutic target and biomarker in cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• The receptor tyrosine kinase c-MET and its ligand, hepatocyte growth factor (HGF), play crucial roles in cell proliferation, invasion, and angiogenesis.
• Aberrant HGF/c-MET signaling is implicated in the pathogenesis of numerous cancers.

Purpose of the Study:

• To review the evidence supporting the HGF/c-MET signaling pathway as a target for personalized cancer treatment.
• To discuss the frequency of c-MET/HGF alterations in various carcinomas.
• To summarize current small molecule inhibitors, antibodies, and resistance mechanisms.

Main Methods:

• Literature review of studies investigating the role of HGF/c-MET in cancer.
• Analysis of data on c-MET and HGF overexpression, activation, and amplification in different cancer types.
• Overview of clinical data for c-MET-targeted therapies and resistance mechanisms.

Main Results:

• High frequencies of c-MET and/or HGF alterations are observed in non-small cell lung carcinoma (NSCLC), gastric, ovarian, pancreatic, thyroid, breast, head and neck, colon, and kidney carcinomas.
• Small molecule inhibitors (e.g., tivantinib) and c-MET/HGF antibodies (e.g., rilotumumab, MetMAb) are under investigation.
• Mechanisms of resistance to c-MET-targeted therapies are being elucidated.

Conclusions:

• The HGF/c-MET pathway represents a significant therapeutic target for personalized cancer treatment across multiple tumor types.
• Further research into targeted therapies and overcoming resistance is crucial for clinical efficacy.